Holly Smith
Critical Care Medicine · Wilmington, NCNPI 1326486176
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 204 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Boehringer Ingelheim at 24.8% of the total. Reporting peaked in 2022 at $1,822 and has fallen 99.2% since, to $14 in 2025.
Across 204 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$935
- AstraZeneca$649
- Philips North America LLC$484
- GSK$393
- Takeda Pharmaceuticals U.S.A., Inc.$345
- Insmed, Inc.$162
- plus $799 from 18 others
What the payments were for
- Food & beverage$3,72299%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 44 | $935 |
| AstraZeneca | 27 | $649 |
| Philips North America LLC | 32 | $484 |
| GSK | 34 | $393 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $345 |
| Insmed, Inc. | 11 | $162 |
| Jazz Pharmaceuticals Inc. | 6 | $123 |
| Mallinckrodt Hospital Products Inc. | 5 | $104 |
| Sanofi | 4 | $100 |
| Mylan Specialty L.p. | 4 | $69 |
| Harmony Biosciences LLC | 2 | $63 |
| Teva Pharmaceuticals USA, Inc. | 4 | $63 |
| Grifols USA, LLC | 3 | $50 |
| Genentech USA, Inc. | 2 | $42 |
| United Therapeutics Corporation | 2 | $38 |
| Merck | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Gilead | 1 | $17 |
| Resmed Corp | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| CSL Behring | 1 | $13 |
| Phadia US Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,767 in reported general payments places this provider in the 85th percentile of 190 critical care medicine providers in North Carolina.
See all critical care medicine providers in North Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $25,100 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $16,801 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $955 |
| Montelukast Sodium | 16 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $393 | $25,10018 claims |
| AstraZenecaBreztri Aerosphere | $649 | $16,80111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 190 critical care medicine providers in North Carolina.
Other critical care medicine in Wilmington
- Alexis SmithHuntersville$726K
- Rabih BecharaCharlotte$453K
- Ashish KhannaWinston Salem$364K
- Alan HeffnerCharlotte$326K
- Daniel FeinsteinPinehurst$213K
- Daniel FoxRaleigh$133K
- Hassan YousafWinston Salem$97K
- Neil MacintyreDurham$70K
- Andrea MacdonaldRaleigh$67K
- John DotyCharlotte$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.